Trials / Active Not Recruiting
Active Not RecruitingNCT06532344
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7913 | Specified dose on specified days |
| DRUG | ONO-4538 | Specified dose on specified days |
| DRUG | Oxaliplatin | Specified dose on specified days |
| DRUG | Levofolinate | Specified dose on specified days |
| DRUG | Irinotecan | Specified dose on specified days |
| DRUG | Fluorouracil | Specified dose on specified days |
Timeline
- Start date
- 2021-07-30
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-08-01
- Last updated
- 2024-11-14
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06532344. Inclusion in this directory is not an endorsement.